Alnylam Pharmaceuticals (ALNY)
Develops and commercializes RNAi medicines led by the AMVUTTRA-centered TTR franchise.
Something off on this page? Send us feedback.
Develops RNAi medicines through a delivery platform spanning lipid nanoparticles and subcutaneous GalNAc conjugates. Directly commercialized products include AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO, while partners sell Leqvio and Qfitlia; commercial results increasingly depend on AMVUTTRA and the TTR franchise.
Develops and commercializes RNA-interference medicines that silence disease-linked messenger RNA. Direct products include AMVUTTRA and ONPATTRO in transthyretin amyloidosis, alongside GIVLAARI and OXLUMO for rare diseases; Leqvio and Qfitlia are commercialized by partners.
Builds its pipeline around delivery chemistry. Lipid nanoparticles enabled intravenous ONPATTRO, while subcutaneous GalNAc conjugates became the main architecture for durable dosing and support AMVUTTRA's quarterly administration. Newer ESC+ and C16 designs seek to reach additional tissues.
Depends increasingly on AMVUTTRA and the TTR franchise after cardiomyopathy approval widened its market and the newer therapy displaced ONPATTRO commercially. Product growth still rests on regulatory approvals and clinical benefit-risk evidence; the revusiran termination remains the clearest example of that development dependency.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 8, 2026 | Jefferies | Reiterate | Rating: —Target: $230 | Target: $260 |
| Aug 28, 2026 | Jefferies | Target | Target: $205 | Target: $230 |
| Aug 25, 2026 | Bernstein | Reiterate | Rating: —Target: $447 | Target: $376 |
| Aug 18, 2026 | BMO Capital | Initiate | Rating: —Target: $470 | Target: $318 |
| Aug 14, 2026 | Wells Fargo | Reiterate | Rating: —Target: $376 | Target: $256 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $3.31B · Total debt $1.27B · Total assets $5.56B · Shareholders' equity $1.35B
- Revenue
- $1.29B
- Operating income
- $231.4M
- Net income
- $164.5M
No dividends on record.
| Institutions | ≈ 100.14% | 134.00M shares | |
|---|---|---|---|
| 828 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.24% | 316.0K shares | |
| 19 holders · as of Sep 22, 2026 | |||
| Adds to | 100.38% | ||
133.81M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 100.38%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 11.23% | 15.02M | as of Jun 30, 2026 |
Capital World InvestorsInstitution | 8.33% | 11.14M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 8.15% | 10.91M | as of Jun 30, 2026 |
Capital Research Global InvestorsInstitution | 7.29% | 9.75M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 4.89% | 6.54M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 1, 2026 | David E. I. Pyott | director | −3,830 | $299.18 |
| Apr 6, 2026 | Melissa McLaughlin | officer: Chief Human Resources Officer | −2,286 | $330.42 |
| Apr 2, 2026 | Melissa McLaughlin | officer: Chief Human Resources Officer | −1,624 | $319.59 |
| Mar 5, 2026 | Kevin Joseph Fitzgerald | officer: CSO & EVP, Head of Research | −658 | $323.98 |
| Mar 4, 2026 | Kevin Joseph Fitzgerald | officer: CSO & EVP, Head of Research | −633 | $323.08 |
- Pfizer
Established oral TTR stabilizer franchise in ATTR cardiomyopathy
- BridgeBio Pharma
Oral Attruby challenger in the core ATTR cardiomyopathy market
- Ionis Pharmaceuticals
Antisense TTR silencing and a broad RNA-targeted drug platform
- Novo Nordisk (ADR)
Competing RNAi medicine for primary hyperoxaluria type 1
- Intellia Therapeutics
One-time CRISPR candidate targeting both major ATTR manifestations
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals | $247.47 | −1.66% | $33.67B | 42.5 | 29.4 | 7.0 | +66.9% |
| Pfizer | $28.04 | +0.38% | $159.19B | 36.9 | 10.0 | 2.5 | +2.6% |
| BridgeBio Pharma | $66.14 | −4.47% | $13.56B | — | — | 19.6 | +120.4% |
| Ionis Pharmaceuticals | $43.33 | −5.30% | $7.60B | — | — | 8.7 | −40.7% |
| Novo Nordisk (ADR) | $38.41 | −2.51% | $174.96B | 9.9 | 15.8 | 3.5 | +1.3% |
| Intellia Therapeutics | $12.16 | −4.22% | $1.77B | — | — | 29.8 | −46.2% |
| Median | 23.4 | 12.9 | 8.7 | +1.3% |